New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients

GSK plc (LSE/NYSE: GSK) today announced new 48-week data from the MOMENTUM phase III trial that showed a majority of patients treated with investigational momelotinib maintained their responses across key clinical measures including Total Symptom Score (TSS), Transfusion Independence (TI) rate, and Splenic Response Rate (SRR) in myelofibrosis patie

Related Keywords

United States ,United Kingdom ,American ,Hesham Abdullah ,American Society Of Hematology ,European Medicines Agency ,Global Head Of Oncology Development ,Drug Administration ,London United Kingdom ,Total Symptom Score ,Transfusion Independence ,Splenic Response Rate ,American Society ,Annual Meeting ,Senior Vice President ,Global Head ,Oncology Development ,Myelofibrosis Symptom Assessment ,New Drug Application ,Marketing Authorisation Application ,Disease ,Medical Specialties ,Nasdaq ,Pharmaceuticals ,Androstanes ,Antiestrogens ,Blood Transfusion ,Clinical Endpoint ,Danazol ,Hormones ,Myelofibrosis ,Teratogens ,